NEW YORK (GenomeWeb News) – Synthetic biology firm Gen9 has raised $395,000 toward a $2 million round, the company said in a regulatory document filed Tuesday.

In its Form D filed with the US Securities and Exchange Commission, the Cambridge, Mass.-based firm said that the funds raised were in the form of debt. Kevin Munnelly, its president and chief business officer, told GenomeWeb Daily News in an e-mail today that proceeds will be used to commercialize the company's products.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.